Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
SALT LAKE CITY, May 31, 2017 -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four Seasons Hotel in Chicago, Illinois.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad’s website at www.myriad.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.
Media Contact: Ron Rogers (801) 584-3065 [email protected] Investor Contact: Scott Gleason (801) 584-1143 [email protected]
